You searched for "correction"

3128 results found

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

BT as a diagnostic tool in Duane’s retraction syndrome

This study evaluated the effects of botulinum-toxin (BT) on management of Duane’s retraction syndrome along with how BT can be used diagnostically to help with patient expectations and decide management. Functional and psychosocial impact of BT effect was evaluated in...

Building Capacity for Children’s Eye Care in Africa: the VISION 2020 LINKS Programme

This article follows the Correspondent News articles in the previous five print issues of Eye News [1-5] on the VISION 2020 LINKS Programme [6]. This article describes how African and UK eye care teams are working together to tackle childhood...

Clinical features and mortality of endogenous panophthalmitis in China

This longitudinal cohort study aimed to report the clinical features, treatment strategy, and mortality of 15 consecutive patients (16 eyes) with endogenous panophthalmitis (EP) at a tertiary medical centre of the largest eye centre in Northern China. Mean age was...

Dry eye disease treatments come to the fore at 100%

Guidance on setting up, or enhancing, a Dry Eye disease clinic within the practice will be freely available from OSA members exhibiting at 100% Optical: 1–3 March. The ability to diagnose and treat a major irritation for many is winning...

Ocular mucous membrane pemphigoid: the importance of early detection and treatment

Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder that is characterised by subepithelial bullae. The ocular manifestation of MMP, ocular mucous membrane pemphigoid (OMMP), is a sight-threatening condition characterised by conjunctival cicatricial changes associated with corneal vascularisation and scarring....

Combined ranibizumab and ablative therapy for Coat’s disease

The aim of this study was to observe the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation or cryotherapy, for Coats’ disease. Patients younger than 16 years of age who were diagnosed with Coats’ disease were included in this...

Effectiveness and Safety of Dexamethasone implants for post surgical macular oedema including Irvine-gass syndrome

This is a retrospective, multicentre, uncontrolled, consecutive case series from Lyon, France between April 20111 to June 2014, with minimum of one year follow-up. The clinical features including the best corrected acuity (BCVA), central subfield macular thickness (CSMT) and intraocular...

Use of reduced volume BT as a treatment option for acute onset comitant esotropia

In this study, the effectiveness and safety of botulinum toxin (BT) for patients with acute acquired comitant esotropia (AACE) and deviation ≤25PD was investigated with comparison of results to conservative prism therapy. Botulinum toxin was undertaken without electromyographic guidance and...

SEEN by Joshua

They were all SEEN by one individual who then took their story to the world to witness. He saw them through his eyes and captured them in his camera lens. Through his vision and through their visual interpretations, an extraordinary,...

Beyond the Snellen Chart: Essential ophthalmology skills for a junior doctor

Despite the clinical weight of the field, ophthalmology was a specialty we encountered infrequently during our early medical training. In spite of limited formal exposure during undergraduate and postgraduate training, eye-related presentations were a regular feature of our day-to-day work...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...